Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2014. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility (PDMRs) regarding changes in their interests in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of share transactions rather than a financial performance report.
Material Changes
The material change disclosed is the purchase of Ordinary Shares by specific directors and connected persons on April 4, 2014. These purchases were executed at a price of 1,583.14 pence per share and resulted from the re-investment of dividends on shares held within Individual Savings Accounts (ISAs).
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly details compliance with Disclosure and Transparency Rule 3.1.4R(1)(a) and (c).
Important Facts for Investors
- Transaction Date: April 4, 2014.
- Share Price: 1,583.14 pence per Ordinary Share.
- Transaction Type: Dividend re-investment within ISAs.
- Directors Involved: Sir Andrew Witty (72 shares), Mr S M Bicknell (97 shares), Mr D S Redfern (18 shares), and Mrs V A Whyte (15 shares).
- Connected Person: Lady C Witty acquired 7 shares.